[{"id":"a498e32c-b2f0-40fb-8597-93fddf2b2869","acronym":"","url":"https://clinicaltrials.gov/study/NCT06034275","created_at":"2023-09-13T14:09:45.731Z","updated_at":"2024-07-02T16:35:23.633Z","phase":"Phase 1","brief_title":"Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","source_id_and_acronym":"NCT06034275","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIP943"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-12"}]